ISSN 1673-3770 CN 37-1437/R
山东大学耳鼻喉眼学报 ›› 2026, Vol. 40 ›› Issue (6): 63-69.
• 气道变态反应性疾病：从机制到实践 • 上一篇
汤玉晨1,王燕1,陶泽璋1,2
TANG Yuchen1, WANG Yan1, TAO Zezhang1,2
摘要： 过敏性鼻炎是一种与Th1/Th2及Th17/Treg免疫失衡相关的鼻腔慢性炎性疾病,其发生发展受到多种先天及后天因素的影响。Toll样受体(toll-like receptors, TLRs)作为模式识别受体中的一种,不仅在鼻腔对外界病原的免疫防御中起到了重要作用,也是适应性免疫的形成过程中的重要角色,与T细胞的成熟分化密切相关。TLR相关免疫制剂的应用在过敏性鼻炎、哮喘等变应性疾病中已得到了一定的临床进展。本文着重对TLR在过敏性的发展及治疗中的研究进展进行论述。
中图分类号:
| [1] Naclerio R, Ansotegui I J, Bousquet J, et al. International expert consensus on the management of allergic rhinitis(AR)aggravated by air pollutants: impact of air pollution on patients with AR: current knowledge and future strategies[J]. World Allergy Organ J, 2020, 13(3): 100106. DOI:10.1016/j.waojou.2020.100106 [2] Wise S K, Damask C, Roland L T, et al. International consensus statement on allergy and rhinology: allergic rhinitis-2023[J]. Int Forum Allergy Rhinol, 2023, 13(4): 293-859. DOI:10.1002/alr.23090 [3] 中华耳鼻咽喉头颈外科杂志编辑委员会鼻科组, 中华医学会耳鼻咽喉头颈外科学分会鼻科学组、小儿学组. 儿童变应性鼻炎诊断和治疗指南(2022年,修订版)[J]. 中华耳鼻咽喉头颈外科杂志, 2022, 57(4): 392-404. DOI:10.3760/cma.j.cn115330-20220303-00092 [4] Li D Y, Wu M H. Pattern recognition receptors in health and diseases[J]. Signal Transduct Target Ther, 2021, 6(1): 291. DOI:10.1038/s41392-021-00687-0 [5] Gao W, Xiong Y, Li Q, et al. Inhibition of toll-like receptor signaling as a promising therapy for inflammatory diseases: a journey from molecular to nano therapeutics[J]. Front Physiol, 2017, 8: 508. DOI:10.3389/fphys.2017.00508 [6] Suzuki M, Cooksley C, Suzuki T, et al. TLR signals in epithelial cells in the nasal cavity and paranasal sinuses[J]. Front Allergy, 2021, 2: 780425. DOI:10.3389/falgy.2021.780425 [7] Ekman A K, Virtala R, Fransson M, et al. Systemic up-regulation of TLR4 causes lipopolysaccharide-induced augmentation of nasal cytokine release in allergic rhinitis[J]. Int Arch Allergy Immunol, 2012, 159(1): 6-14. DOI:10.1159/000335196 [8] Tengroth L, Millrud C R, Kvarnhammar A M, et al. Functional effects of Toll-like receptor(TLR)3, 7, 9, RIG-I and MDA-5 stimulation in nasal epithelial cells[J]. PLoS One, 2014, 9(6): e98239. DOI:10.1371/journal.pone.0098239 [9] Renkonen J, Toppila-Salmi S, Joenväärä S, et al. Expression of Toll-like receptors in nasal epithelium in allergic rhinitis[J]. APMIS, 2015, 123(8):716-725. DOI: 10.1111/apm.12408 [10] Cui X Y, Chen X, Yu C J, et al. Increased expression of toll-like receptors 2 and 4 and related cytokines in persistent allergic rhinitis[J]. Otolaryngol Head Neck Surg, 2015, 152(2): 233-238. DOI:10.1177/0194599814562173 [11] Zhu X W, Cong J N, Yang B, et al. Association analysis of high-mobility group box-1 protein 1(HMGB1)/toll-like receptor(TLR)4 with nasal interleukins in allergic rhinitis patients[J]. Cytokine, 2020, 126: 154880. DOI:10.1016/j.cyto.2019.154880 [12] Wang L H, Zhan M M, Wang J L, et al. Upregulated expression of toll-like receptor 7 in peripheral blood basophils of patients with allergic rhinitis[J]. Am J Rhinol Allergy, 2021, 35(6): 746-760. DOI:10.1177/1945892421993034 [13] Bergougnan C, Dittlein D C, Hümmer E, et al. Physical and immunological barrier of human primary nasal epithelial cells from non-allergic and allergic donors[J]. World Allergy Organ J, 2020, 13(3): 100109. DOI:10.1016/j.waojou.2020.100109 [14] Clarke T B, Francella N, Huegel A, et al. Invasive bacterial pathogens exploit TLR-mediated downregulation of tight junction components to facilitate translocation across the epithelium[J]. Cell Host Microbe, 2011, 9(5): 404-414. DOI:10.1016/j.chom.2011.04.012 [15] Ohkuni T, Kojima T, Ogasawara N, et al. Poly(I: C)reduces expression of JAM-A and induces secretion of IL-8 and TNF-α via distinct NF-κB pathways in human nasal epithelial cells[J]. Toxicol Appl Pharmacol, 2011, 250(1): 29-38. DOI:10.1016/j.taap.2010.09.023 [16] Ryu J H, Yoo J Y, Kim M J, et al. Distinct TLR-mediated pathways regulate house dust mite-induced allergic disease in the upper and lower airways[J]. J Allergy Clin Immunol, 2013, 131(2): 549-561. DOI:10.1016/j.jaci.2012.07.050 [17] Kim G, Hong M, Kashif A, et al. Der f 38 is a novel TLR4-binding allergen related to allergy pathogenesis from Dermatophagoides farinae[J]. Int J Mol Sci, 2021, 22(16): 8440. DOI:10.3390/ijms22168440 [18] Ebrahim Soltani Z, Badripour A, Haddadi NS, et al. Allergic rhinitis in BALB/c mice is associated with behavioral and hippocampus changes and neuroinflammation via the TLR4/NF-κB signaling pathway[J]. Int Immunopharmacol, 2022, 108: 108725. DOI:10.1016/j.intimp.2022.108725 [19] Li D Q, Zhang L L, Pflugfelder S C, et al. Short ragweed pollen triggers allergic inflammation through Toll-like receptor 4-dependent thymic stromal lymphopoietin/OX40 ligand/OX40 signaling pathways[J]. J Allergy Clin Immunol, 2011, 128(6): 1318-1325.e2. DOI:10.1016/j.jaci.2011.06.041 [20] Zheng R, Chen F H, Gao W X, et al. The TH2-polarizing function of atopic interleukin 17 receptor B-positive dendritic cells up-regulated by lipopolysaccharide[J]. Ann Allergy Asthma Immunol, 2017, 118(4): 474-482.e1. DOI:10.1016/j.anai.2016.12.011 [21] Zheng R, Chen Y, Shi J B, et al. Combinatorial IL-17RB, ST2, and TSLPR signaling in dendritic cells of patients with allergic rhinitis[J]. Front Cell Dev Biol, 2020, 8: 207. DOI:10.3389/fcell.2020.00207 [22] Deifl S, Kitzmüller C, Steinberger P, et al. Differential activation of dendritic cells by toll-like receptors causes diverse differentiation of na ve CD4+ T cells from allergic patients[J]. Allergy, 2014, 69(12): 1602-1609. DOI:10.1111/all.12501 [23] Eisenbarth S C, Piggott D A, Huleatt J W, et al. Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen[J]. J Exp Med, 2002, 196(12): 1645-1651. DOI:10.1084/jem.20021340 [24] Volpi C, Fallarino F, Pallotta M T, et al. High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway[J]. Nat Commun, 2013, 4: 1852. DOI:10.1038/ncomms2874 [25] Thio C L, Lai A C, Chi P Y, et al. Toll-like receptor 9-dependent interferon production prevents group 2 innate lymphoid cell-driven airway hyperreactivity[J]. J Allergy Clin Immunol, 2019, 144(3): 682-697.e9. DOI:10.1016/j.jaci.2019.03.008 [26] Crellin N K, Garcia R V, Hadisfar O, et al. Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells[J]. J Immunol, 2005, 175(12): 8051-8059. DOI:10.4049/jimmunol.175.12.8051 [27] Round J L, Mazmanian S K. Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota[J]. Proc Natl Acad Sci U S A, 2010, 107(27): 12204-12209. DOI:10.1073/pnas.0909122107 [28] Zhao M, Zeng H T, Yang G, et al. Toll-like receptor signal is required in maintenance of immune suppressive capacity of regulatory T cells[J]. Immunol Lett, 2019, 210: 47-54. DOI:10.1016/j.imlet.2019.04.005 [29] Rouadi P W, Idriss S A, Naclerio R M, et al. Immunopathological features of air pollution and its impact on inflammatory airway diseases(IAD)[J]. World Allergy Organ J, 2020, 13(10): 100467. DOI:10.1016/j.waojou.2020.100467 [30] Fonceca A M, Zosky G R, Bozanich E M, et al. Accumulation mode particles and LPS exposure induce TLR-4 dependent and independent inflammatory responses in the lung[J]. Respir Res, 2018, 19(1): 15. DOI:10.1186/s12931-017-0701-z [31] Ege M J, Bieli C, Frei R, et al. Prenatal farm exposure is related to the expression of receptors of the innate immunity and to atopic sensitization in school-age children[J]. J Allergy Clin Immunol, 2006, 117(4): 817-823. DOI:10.1016/j.jaci.2005.12.1307 [32] Stein M M, Hrusch C L, Gozdz J, et al. Innate immunity and asthma risk in Amish and Hutterite farm children[J]. N Engl J Med, 2016, 375(5): 411-421. DOI:10.1056/NEJMoa1508749 [33] Yu N, Weng Y M, Liu W, et al. TLRs induce Th1/Th2 responses by affecting the secretion of CCL2 at the maternal-foetal interface[J]. Int Immunopharmacol, 2021, 100: 108070. DOI:10.1016/j.intimp.2021.108070 [34] Yu J Y, Liu X Q, Li Y L, et al. Maternal exposure to farming environment protects offspring against allergic diseases by modulating the neonatal TLR-Tregs-Th axis[J]. Clin Transl Allergy, 2018, 8: 34. DOI:10.1186/s13601-018-0220-0 [35] Golebski K, van Tongeren J, van Egmond D, et al. Specific induction of TSLP by the viral RNA analogue poly(I: C)in primary epithelial cells derived from nasal polyps[J]. PLoS One, 2016, 11(4): e0152808. DOI:10.1371/journal.pone.0152808 [36] Suzuki M, Ramezanpour M, Cooksley C, et al. Sirtuin-1 controls poly(I: C)-dependent matrix metalloproteinase 9 activation in primary human nasal epithelial cells[J]. Am J Respir Cell Mol Biol, 2018, 59(4): 500-510. DOI:10.1165/rcmb.2017-0415OC [37] Ellis A K, Tsitoura D C, Quint D, et al. Safety and pharmacodynamics of intranasal GSK2245035, a TLR7 agonist for allergic rhinitis: a randomized trial[J]. Clin Exp Allergy, 2017, 47(9): 1193-1203. DOI:10.1111/cea.12974 [38] Psallidas I, Backer V, Kuna P, et al. A phase 2a, double-blind, placebo-controlled randomized trial of inhaled TLR9 agonist AZD1419 in asthma[J]. Am J Respir Crit Care Med, 2021, 203(3): 296-306. DOI:10.1164/rccm.202001-0133OC [39] Jensen-Jarolim E, Roth-Walter F, Jordakieva G, et al. Allergens and Adjuvants in Allergen Immunotherapy for Immune Activation, Tolerance, and Resilience[J]. J Allergy Clin Immunol Pract, 2021, 9(5): 1780-1789. DOI:10.1016/j.jaip.2020.12.008 [40] Starchenka S, Heath M D, Lineberry A, et al. Transcriptome analysis and safety profile of the early-phase clinical response to an adjuvanted grass allergoid immunotherapy[J]. World Allergy Organ J, 2019, 12(11): 100087. DOI:10.1016/j.waojou.2019.100087 [41] Starchenka S, Oluwayi K, Heath M, et al. Peripheral blood mononuclear cell transcriptome profile in a clinical trial with subcutaneous, grass pollen allergoid immunotherapy[J]. Clin Exp Allergy, 2024, 54(2): 130-142. DOI:10.1111/cea.14432 [42] Worm M, Higenbottam T, Pfaar O, et al. Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy[J]. Allergy, 2018, 73(9): 1812-1822. DOI:10.1111/all.13478 [43] Florido-López J F, Andreu-Balaguer C, Escudero C, et al. Effectiveness and safety of a glutaraldehyde-modified, L-tyrosine-adsorbed and monophosphoryl lipid A-Adjuvanted allergen immunotherapy in patients with allergic asthma sensitized to olive pollen: a retrospective, controlled real-world study[J]. World Allergy Organ J, 2020, 13(12): 100487. DOI:10.1016/j.waojou.2020.100487 [44] de Kam P J, Zielen S, Bernstein J A, et al. Short-course subcutaneous treatment with PQ Grass strongly improves symptom and medication scores in grass allergy[J]. Allergy, 2023, 78(10): 2756-2766. DOI:10.1111/all.15788 [45] Senti G, Johansen P, Haug S, et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial[J]. Clin Exp Allergy, 2009, 39(4): 562-570. DOI:10.1111/j.1365-2222.2008.03191.x [46] Ellis A K, Tsitoura D C, Quint D, et al. Safety and pharmacodynamics of intranasal GSK2245035, a TLR7 agonist for allergic rhinitis: a randomized trial[J]. Clin Exp Allergy, 2017, 47(9): 1193-1203. DOI:10.1111/cea.12974 [47] Klimek L, Willers J, Hammann-Haenni A, et al. Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study[J]. Clin Exp Allergy, 2011, 41(9): 1305-1312. DOI:10.1111/j.1365-2222.2011.03783.x [48] Lin Y J, Papp G, Miskey C, et al. The flagellin: allergen fusion protein rFlaA: Betv1 induces a MyD88- and MAPK-dependent activation of glucose metabolism in macrophages[J]. Cells, 2021, 10(10): 2614. DOI:10.3390/cells10102614 [49] Mo J H, Park S W, Rhee C S, et al. Suppression of allergic response by CpG motif oligodeoxynucleotide-house-dust mite conjugate in animal model of allergic rhinitis[J]. Am J Rhinol, 2006, 20(2): 212-218 [50] 林小燕, 李静, 马志祺, 等. 益生菌治疗变应性鼻炎的临床疗效及抗变态反应作用Meta分析[J]. 山东大学耳鼻喉眼学报, 2021, 35(3): 70-80. DOI:10.6040/j.issn.1673-3770.0.2020.374 [51] Meng Q, Li P, Li Y, et al. Broncho-vaxom alleviates persistent allergic rhinitis in patients by improving Th1/Th2 cytokine balance of nasal mucosa[J]. Rhinology, 2019, 57(6): 451-459. DOI:10.4193/Rhin19.161 [52] Yu J I, Kim J H, Nam K E, et al. Pneumococcal Δpep27 immunization attenuates TLRs and NLRP3 expression and relieves murine ovalbumin-induced allergic rhinitis[J]. J Microbiol Biotechnol, 2022, 32(6): 709-717. DOI:10.4014/jmb.2203.03006 |
| [1] | 刘丹凤,潘庆春,封雪飞,李昊佚,任健,李代波. 老年过敏性鼻炎患者哮喘共病风险预测列线图:多因素模型的构建与临床验证[J]. 山东大学耳鼻喉眼学报, 2026, 40(6): 54-62. |
| [2] | 杜康丽,郑振宇,徐战将,张宇,陈露,卢梦垚. 鼻中隔偏曲并发慢性鼻窦炎风险预测模型的构建与验证[J]. 山东大学耳鼻喉眼学报, 2025, 39(6): 78-86. |
| [3] | 黄焕,华红利,邓玉琴,江承洋,王雨薇,杨星海. 儿童过敏性鼻炎、扁桃体腺样体肥大和鼻窦炎之间相关性及其对临床指导价值[J]. 山东大学耳鼻喉眼学报, 2025, 39(5): 34-41. |
| [4] | 张杰,陈敏,申征征,吴宇华,刘原虎,孙浩,谭新华,倪树仁,杨书勋,史雪峥,倪鑫. 过敏性鼻炎与儿童新冠病毒肺炎感染及症状的关联性研究[J]. 山东大学耳鼻喉眼学报, 2024, 38(4): 36-42. |
| [5] | 晏慧娟,肖旭平,钟宇. IL-29和TLR4在嗜酸性粒细胞浸润鼻息肉中的表达及临床意义[J]. 山东大学耳鼻喉眼学报, 2024, 38(2): 122-127. |
| [6] | 伦英俊,陈晨,高宏程,范清琳,邰仁清. TLR4/NF-κB通道在糖尿病视网膜病变中的作用[J]. 山东大学耳鼻喉眼学报, 2024, 38(2): 163-168. |
| [7] | 张真,杨卓莹,周佳妮,张大为,陈仁杰. 环索奈德鼻喷剂治疗季节性过敏性鼻炎疗效与安全的Meta分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(1): 13-20. |
| [8] | 乌日柴夫,苏日古格,孟永梅. 卵清蛋白诱导的过敏性鼻炎豚鼠模型的建立与评价及蒙医舌尿诊的初步分析[J]. 山东大学耳鼻喉眼学报, 2024, 38(1): 32-38. |
| [9] | 王剑,杜伟嘉,薛涛,陈福权. 利用百度指数分析中国过敏性鼻炎及相关变应性疾病的流行特征[J]. 山东大学耳鼻喉眼学报, 2023, 37(5): 31-41. |
| [10] | 王晓嫒,张欠欠,程翔宇,李志鹏,张维天,叶海波. 翼管神经切断术治疗2型慢性鼻窦炎伴过敏性鼻炎的临床疗效分析[J]. 山东大学耳鼻喉眼学报, 2023, 37(5): 42-49. |
| [11] | 毕晓云,马本绪,王心茹,李旭豪,杨继国. 穴位贴敷治疗小儿过敏性鼻炎随机对照试验的Meta分析[J]. 山东大学耳鼻喉眼学报, 2023, 37(4): 75-85. |
| [12] | 王惟一,时蕾,张志玉,张贵玲,时光刚. 高脂饮食对过敏性鼻炎小鼠致敏影响和肠道菌群改变的研究[J]. 山东大学耳鼻喉眼学报, 2023, 37(3): 21-29. |
| [13] | 张雅琪,刘慧敏,曹淋曼,王子钰,林旭,李燕萍,薛刚,吴靖芳. MAPK、PI3K-AKT、NF-κB在小鼠过敏性鼻炎中的表达及意义[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 254-259. |
| [14] | 庞冲,边赛男,张冰,尹旭,陆颖霞,叶鹏飞,王湛,赵晶,高彦,关凯. 儿童过敏性鼻炎粉尘螨特异性舌下免疫治疗短期疗效评估[J]. 山东大学耳鼻喉眼学报, 2022, 36(1): 70-74. |
| [15] | 王鑫,刘巧平,闫占峰,刘思溟,朱雅静,丁倩,张莹,田媛,张京然. 基于网络药理学探究小青龙汤治疗过敏性鼻炎的作用机制[J]. 山东大学耳鼻喉眼学报, 2021, 35(5): 46-55. |
|
||